Drug
TAC
TAC is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
1
25%
Ph phase_2
3
75%
Phase Distribution
0
Early Stage
3
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
3(75.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(2)
Other(1)
Detailed Status
Completed2
Active, not recruiting1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 23 (75.0%)
Phase 31 (25.0%)
Trials by Status
completed250%
active_not_recruiting125%
unknown125%
Recent Activity
1 active trials
Showing 4 of 4
completedphase_2
A Study of TCD601 in de Novo Renal Transplant Recipients
NCT05669001
active_not_recruitingphase_2
A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation
NCT06019507
unknownphase_2
The Combination of Tacrolimus and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
NCT05471050
completedphase_3
Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer
NCT00544765
Clinical Trials (4)
Showing 4 of 4 trials
NCT05669001Phase 2
A Study of TCD601 in de Novo Renal Transplant Recipients
NCT06019507Phase 2
A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation
NCT05471050Phase 2
The Combination of Tacrolimus and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
NCT00544765Phase 3
Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4